Document Detail


Future therapies: Early trials and basic science.
MedLine Citation:
PMID:  24523838     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Pharmacotherapeutic options for overactive bladder (OAB) include antimuscarinics and the beta3-adrenoceptor agonist mirabegron. Research and development of novel therapeutic options for OAB continues to be an active field. This review summarizes recent research with the existing therapies as well as the most promising agents in development.
Authors:
Karl-Erik Andersson
Related Documents :
24523838 - Future therapies: early trials and basic science.
21980018 - A framework for cancer survivorship research and translation to policy.
15589678 - Contributions of social science to the alcohol field in an era of biomedicalization.
11694198 - Any further progress in smoking cessation treatment?
3848448 - Designing nursing research: the qualitative-quantitative debate.
3580088 - The effects of a specific prompting sign on speed reduction.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Canadian Urological Association journal = Journal de l'Association des urologues du Canada     Volume:  7     ISSN:  1911-6470     ISO Abbreviation:  Can Urol Assoc J     Publication Date:  2013 Sep 
Date Detail:
Created Date:  2014-02-13     Completed Date:  2014-06-24     Revised Date:  2014-06-24    
Medline Journal Info:
Nlm Unique ID:  101312644     Medline TA:  Can Urol Assoc J     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  S179-80     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment considerations for OAB: Case studies.
Next Document:  A urological challenge: Voiding dysfunction in multiple sclerosis.